Question 1

What is Adcendo?

Accepted Answer

Adcendo is a Entity.

Question 2

How often does Adcendo appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Adcendo first tracked by Ergen?

Accepted Answer

First tracked on May 26, 2026.

Question 4

When was Adcendo last mentioned in news?

Accepted Answer

Last active on May 26, 2026.

Question 5

What is Adcendo's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Adcendo in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Adcendo?

Accepted Answer

Adcendo, MSD Collaborate on ADCE-T02, KEYTRUDA (May 26, 2026, 6 articles).

Question 8

How did the "Adcendo, MSD Collaborate on ADCE-T02, KEYTRUDA" event impact Adcendo?

Accepted Answer

Adcendo has entered into a clinical trial collaboration and supply agreement with MSD to evaluate ADCE-T02 in combination with Pembrolizumab. This collaboration is a significant step for Adcendo in advancing its cancer therapies.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.